
The U.K.-based AstraZeneca Plc (NASDAQ:AZN) paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site.
AstraZeneca spokesperson told Reuters the company regularly reviews investment priorities and can confirm that the Cambridge expansion is on hold.